MAXY - Maxygen, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (32)	9/13/2000 5:25:40 PM
From: 2MAR$	Read Replies (1) of 262

Maxygen Awarded Broad Patent Expanding Its Leadership Position in Directed Molecular Evolution biz.yahoo.com As Well: MAXY has signed a follow-on agreement with Pfizer expanding a project designed to improve a biosynthetic pathway essential to the manufacture of one of Pfizer's pharmaceutical products. Financial terms weren't disclosed. In a press release Wednesday, Maxygen said under the expanded collaboration, Pfizer will provide funding for Maxygen to develop its biosynthetic pathway and make milestone payments associated with commercialization goals. In a separate press release, Maxygen said it received a patent expansion for its MolecularBreeding directed molecular evolution technologies. The new patent covers a variety of in vivo DNAShuffling recombination methods and formats, as well as various uses of DNAShuffling. Maxygen creates novel products using directed evolution technologies. -Jason Overdorf; Dow Jones Newswires; 201-938-5400 (END) DOW JONES NEWS 09-13-00 05:29 PM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next